Oragenics, Inc. (OGEN)
- Previous Close
1.7200 - Open
1.7000 - Bid 1.6500 x 800
- Ask 1.7600 x 1200
- Day's Range
1.6617 - 1.7699 - 52 Week Range
1.0000 - 7.7400 - Volume
33,163 - Avg. Volume
111,258 - Market Cap (intraday)
7.483M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-8.4700 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
www.oragenics.comRecent News: OGEN
Performance Overview: OGEN
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OGEN
Valuation Measures
Market Cap
7.48M
Enterprise Value
7.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.25
Enterprise Value/Revenue
105.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-163.28%
Return on Equity (ttm)
-314.88%
Revenue (ttm)
20.63k
Net Income Avi to Common (ttm)
-20.26M
Diluted EPS (ttm)
-8.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.07M
Total Debt/Equity (mrq)
4.83%
Levered Free Cash Flow (ttm)
-10.3M